Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Encapsulated Benzoyl Peroxide Cream
Encapsulated Benzoyl Peroxide · 1 trial · 1 indication
Facial microbiome sampling will be performed on-site by collecting follicular samples as well as utilizing facial swabs.
transepidermal water loss in g/m2/h
stratum corneum water content (wt%)
sebum production in µg/cm2
facial L\*a\*b\* values
| Arm | Type | Description |
|---|---|---|
| Study Drug | EXPERIMENTAL | Daily Encapsulated Benzoyl Peroxide (E-BPO) Cream, for 8 weeks (period 1). Subjects will then switch treatments to the vehicle cream for a period of 4 weeks (period 2), |
| Vehicle | PLACEBO_COMPARATOR | Daily Vehicle Cream, for 8 weeks (period 1). Subjects will then switch treatments to the study drug encapsulated E-BPO for a period of 4 weeks (period 2), |
| Name | Type | Description |
|---|---|---|
| Encapsulated Benzoyl Peroxide Cream | DRUG | Subjects will use a "pea-size" amount for each area of the face |
Inclusion Criteria: * Participants must sign an Institutional Review Board (IRB) approved written informed consent for this study. * Male and female 18 years of age and older. * Participants must have clinical diagnosis of moderate to severe rosacea. * Have a minimum total of 15 and a maximum of 70...
Encapsulated Benzoyl Peroxide is an investigational small molecule dermatology therapy that Sol-Gel Technologies Ltd. (ticker SLGL) is developing for papulopustular rosacea. It is a topical formulation in which the benzoyl peroxide is encapsulated. It is also known as Encapsulated Benzoyl Peroxide Cream.
Encapsulated Benzoyl Peroxide is being studied for papulopustular rosacea, a form of rosacea marked by papules and pustules. The only trial recorded for this asset enrolled adults with that condition. It is investigational and has not been established as a treatment outside of clinical research.
Sol-Gel Technologies Ltd. is developing Encapsulated Benzoyl Peroxide. The company trades under the ticker SLGL. Sol-Gel is the sponsor of the clinical program for this topical dermatology asset.
Encapsulated Benzoyl Peroxide is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. It is an investigational product and is not approved for marketing.
Encapsulated Benzoyl Peroxide has been evaluated in one completed Phase 1 trial, NCT05675501, titled Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties. The trial enrolled 31 participants in the United States with papulopustular rosacea and was randomized, double blind, and placebo controlled.
Yes. Encapsulated Benzoyl Peroxide Cream is another name for Encapsulated Benzoyl Peroxide, the topical dermatology asset that Sol-Gel Technologies Ltd. (ticker SLGL) is developing for papulopustular rosacea. Both names refer to the same investigational product.